Home » Stocks » PDLI

PDL BioPharma, Inc. (PDLI)

Dec 31, 2020 - PDLI was delisted
Stock Price: $2.47 USD 0.00 (0.00%)
Updated Dec 30, 2020 4:00 PM EST - Market closed
Market Cap 282.14M
Revenue (ttm) 13.44M
Net Income (ttm) -154.37M
Shares Out 115.91M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE 64.94
Dividend n/a
Dividend Yield n/a
Trading Day December 30
Last Price $2.47
Previous Close $2.47
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.47 - 2.47
Day's Volume 0
52-Week Range 0.00 - 2.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

RENO, Nev., Dec. 14, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps In...

Seeking Alpha - 1 month ago

PDLI is liquidating, it should delist from the NASDAQ on December 31, 2020. Patient investors can ultimately expect a return of approximately 40% based on net assets.

Seeking Alpha - 2 months ago

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 211.11% year over year to ($0.10)...

PRNewsWire - 2 months ago

INCLINE VILLAGE, Nev., Nov. 11, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 202...

Business Wire - 2 months ago

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment o...

PRNewsWire - 2 months ago

INCLINE VILLAGE, Nev., Nov. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financia...

Zacks Investment Research - 3 months ago

PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Business Wire - 3 months ago

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment o...

PRNewsWire - 4 months ago

INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PRNewsWire - 4 months ago

INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PRNewsWire - 4 months ago

INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

Seeking Alpha - 5 months ago

PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

INCLINE VILLAGE, Nev., Aug. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PRNewsWire - 5 months ago

INCLINE VILLAGE, Nev., July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

Seeking Alpha - 8 months ago

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 10 months ago

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

Seeking Alpha - 10 months ago

PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

The company announced the completion of a strategic review with plans that could mean good news for investors.

Zacks Investment Research - 1 year ago

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well.

Seeking Alpha - 1 year ago

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

A letter from an activist investor to the company's board of directors is lighting a fire beneath this healthcare stock.

Zacks Investment Research - 1 year ago

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 1 year ago

Tracking weekly changes in fundamental and price trend for 5,200 companies.

Other stocks mentioned: APLE, ERA, ERII, GBDC
Zacks Investment Research - 1 year ago

PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.

Seeking Alpha - 1 year ago

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.

Zacks Investment Research - 1 year ago

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

Seeking Alpha - 1 year ago

PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.

Seeking Alpha - 1 year ago

Evofem's lead drug (Amphora) passed Phase 3 clinical trials. Amphora is a differentiated contraception drug. PDL will make an investment in Evofem up to 29% of equity.

Other stocks mentioned: EVFM
Zacks Investment Research - 1 year ago

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Does PDL BioPharma (PDLI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha - 1 year ago

PDL BioPharma is reaching a technical resistance point.

Seeking Alpha - 1 year ago

PDL BioPharma Inc.'s (PDLI) CEO Dominique Monnet on Q4 2018 Results - Earnings Call Transcript

About PDLI

PDL BioPharma manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Industry
Biotechnology
IPO Date
Jan 28, 1992
CEO
John McLaughlin
Employees
109
Stock Exchange
NASDAQ
Ticker Symbol
PDLI
Full Company Profile

Financial Performance

In 2019, PDL BioPharma's revenue was $54.76 million, a decrease of -72.36% compared to the previous year's $198.11 million. Losses were -$70.41 million, 2.25% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for PDL BioPharma is 2.50, which is an increase of 1.21% from the latest price.

Price Target
$2.50
(1.21% upside)